Hypofibrinogenemia caused by a novel FGG missense mutation (W253C) in the γ chain globular domain impairing fibrinogen secretion

D Vu, P de Moerloose, A Batorova, J Lazur, L Palumbo, M Neerman-Arbez

Background: Inherited disorders of fibrinogen are rare and affect either the quantity (hypofibrinogenemia and afibrinogenemia) or the quality of the circulating fibrinogen (dysfibrinogenemia). Extensive allelic heterogeneity has been found for all three disorders: in congenital afibrinogenemia >30 mutations, the majority in FGA, have been identified in homozygosity or in compound heterozygosity. Several mutations have also been identified in patients with hypofibrinogenemia; many of these are heterozygous carriers of afibrinogenemia null mutations.

Objective: To report the case of a patient from Slovakia diagnosed with hypofibrinogenemia characterised by fibrinogen concentrations of around 0.7 g/l.

Results: The patient was found to be heterozygous for a novel missense mutation W253C (W227C in the mature chain) in the C-terminal globular domain of the fibrinogen γ chain. Co-expression of the W253C FGG mutant cDNA (fibrinogen Bratislava) in combination with wild-type FGA and FGB cDNAs showed that fibrinogen molecules containing the mutant γ chain can assemble intracellularly but are not secreted into the media, confirming the causative nature of the identified mutation.

Conclusions: Current analysis of fibrinogen Bratislava indicates that the domains important for the processes of hexamer assembly and hexamer secretion should not be considered as strictly restricted to one or other fibrinogen chain.

Fibrin is the major protein of the blood clot and is necessary for the mechanical binding of platelets and other plasma proteins, forming a network of fibrin polymers to prevent blood flow from an injured vessel. Fibrinogen is produced following proteolytic cleavage of fibrinogen by thrombin which allows polymerisation to occur.1 Fibrinogen is a 340 kDa glycoprotein predominantly synthesised by hepatocytes; it is composed of two sets of three homologous polypeptide chains known as Aα-, Bβ-, and γ chains, which assemble to form a hexameric structure (Aα2Bβ2γ1). Each polypeptide is encoded by a distinct gene, FGA, FGB, and FGG, respectively, clustered in a region of 50 kb on chromosome 4q31.2

Fibrinogen is normally found in plasma at concentrations of between 1.5 and 3.5 g/l. Inherited disorders of fibrinogen are rare and affect either the quantity (hypofibrinogenemia and afibrinogenemia) or the quality of the circulating fibrinogen (dysfibrinogenemia). More than 400 cases of dysfibrinogenemia have been reported to date, the first dysfibrinogenemia mutation being identified as early as 1968.3 The majority of dysfibrinogenemia are caused by missense mutations in one of the three fibrinogen genes. Missense mutations at residue R35 (R35H and R35C, or R16H and R16C in the mature protein), which is part of the thrombin cleavage site in the fibrinogen γ chain, are the most common. In contrast, the molecular basis of afibrinogenemia/hypofibrinogenemia has only recently become elucidated.

Congenital afibrinogenemia is characterised by complete deficiency of fibrinogen. In 1999, we identified the first causative mutations for congenital afibrinogenemia: the genetic defect in a non-consanguineous Swiss family was an apparently recurrent deletion of approximately 11 kb of DNA which eliminates the majority of the FGA gene and so leads to a complete absence of functional fibrinogen.4 Since our identification of the disease locus, numerous causative mutations have been characterised in FGA (the great majority of cases5–7) but also in FGG and FGB, allowing a precise molecular diagnosis for the patients as well as prenatal diagnosis for the families concerned.

Of particular interest are missense mutations leading to complete fibrinogen deficiency: four such missense mutations have been described in FGB: L138R, G430D, G444S,8 and W467G,9 numbered from the initiator ATG. These missense mutations all lie in the C terminal portion of the fibrinogen β chain, which is highly conserved among vertebrates. In addition, two nonsense mutations in the same region were recently characterised. The first, W470X, was identified in heterozygosity in an asymptomatic patient.10 The second nonsense mutation, W467X, three codons upstream, was identified in homozygosity in two Palestinian sisters with afibrinogenemia and results in a fibrinogen β chain which lacks only the last 25 amino acid residues.11 Expression studies in transfected cells performed for the four missense and the W467X β chain C-terminal mutations both in our laboratory and by others showed that an intact β C-terminal domain is necessary for hexamer secretion into the circulation, although assembly inside the cell appears unimpaired. Interestingly, this property of the fibrinogen β chain seems to differ from the C-terminus of the fibrinogen γ chain, which has been shown to be necessary for intracellular hexamer assembly in experiments investigating serial deletions of the γ C-terminus,12 but also in studies on hypofibrinogenemia mutants such as fibrinogen Matsumoto IV.13,14

Congenital hypofibrinogenemia is characterised by functional and antigenic fibrinogen levels lower than 1.5 g/l. Although in the past hypofibrinogenemia was considered a separate disorder from afibrinogenemia, with both dominant and recessive modes of inheritance proposed, recent studies (reviewed by Maghzal et al15) have shown that in

Abbreviations: ATG, annotated translation start codon; CHO, Chinese hamster ovary
many cases patients are asymptomatic and are in fact heterozygous for null mutations which in homozygosity or compound heterozygosity would cause afibrinogenaemia.

In this study, a patient with hypofibrinogenaemia was found to be heterozygous for a novel missense mutation in FGG: TGG→TGT, W253C (W227 in the mature protein) in exon 7. The localisation of this missense mutation close to the previously reported mutations Matsumoto IV13 and Hakata15 prompted us to carry out co-transfection experiments in COS-7 cells in order to assay its consequence on fibrinogen assembly or secretion and to confirm its causative nature.

METHODS

Clinical description
The patient, a woman now aged 38, with no family history of bleeding, was diagnosed with hypofibrinogenaemia at the age of 22 years after a bleeding complication of delivery. Her father and mother died at the age of 70 and 63 years, from myocardial infarction and a brain tumour, respectively. The patient suffered from frequent epistaxis during childhood, mild bleeding after tooth extractions, and prolonged wound bleeding and healing, none however requiring therapeutic intervention. Menarche and subsequent menstrual bleedings were normal. Hypofibrinogenaemia was diagnosed on the basis of low fibrinogen levels (0.7 g/l) after the first spontaneous delivery was complicated by serious bleeding and the development of a large pararectal haematoma. The patient received three units of red blood cells and a surgical revision was made after an infusion of 3.0 g of fibrinogen concentrate (Fibrinogen, Immuno, Vienna, Austria). At the age of 28 years she had a missed abortion in the first trimester. Mild bleeding occurred again at the age of 31 years after a second spontaneous delivery managed by replacement of 3.0 grams of fibrinogen, which increased the circulating fibrinogen to 1.6 g/l. At the age of 38 years the patient underwent laparoscopic surgery after preoperative administration of 3.0 g fibrinogen, without any bleeding complications.

Coagulation studies
Prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and functional factors II, V, VII, VIII, IX, X, and von Willebrand antigen were measured using reagents, calibrators, and factor deficient plasmas from Dade Behring (Marburg, Germany). Fibrin/fibrinogen degradation products levels were determined with Thrombo-Welcotest (Bistech, Murex, Dartford, UK) and D-dimer with DD-Plus (Dade Behring, Berlin, Germany). Clotable fibrinogen was measured with the Clauss method and fibrinogen antigen with Turbiquant fibrinogen using a Turbitimer (both from Dade Behring). Bleeding time was measured according to Duke, and the euglobulin lysis time (ELT) by standard methods. After obtaining informed consent from the patient, blood was collected in EDTA for DNA analysis.

Mutation screening
All exons and intron-exon junctions of the FGA, FGG, and FGB genes were amplified by polymerase chain reaction (PCR) and sequenced as previously described.3,16

Expression and analysis of the mutations in COS-7 cells
Construction of wild type and mutant expression vectors, transient co-transfections of COS-7 cells, cell lysate and conditioned media harvesting, and western blot analysis were carried out essentially as previously described,17 with some minor modifications. The forward oligonucleotides used for site-directed mutagenesis were: 5’-GCACAACAG AATTCTGTCTGGGAAATGAGAAG-3’ for the Trp253Cys substitution (highlighted in bold); 5’-CCACTGAGATATAG CCATTCAACAGACTCAC-3’ for Ile413stop; 5’-GAAGAAAACC ACTATGAGATAATCCATTCAAC-3’ for Lys411stop, and 5’-GGGTGGATCCATGTAGAAAAACACTAGT-3’ for Lys406stop with the inserted stop codon in bold. The whole cDNA sequence of all mutants was confirmed by sequencing. Twenty four hours after transfection, cells were washed with phosphate buffered saline (PBS) and incubated for an
additional 24 hours in media without serum. Conditioned medium with added proteases inhibitors (Complete, Roche) was concentrated using Amicon Ultra-4 5 kDa (Millipore) and cells were scraped in Ripa buffer before addition of reducing or non-reducing 4× Laemmli buffer. Independent experiments were repeated three times. Western blot analysis was undertaken using rabbit antihuman fibrinogen antibodies (DakoCytomation) at a 1:2500 or 1:1500 dilution, or mouse antiactin antibodies (1:2500; Chemicon).

Figure 2. Multiple alignment of fibrinogen γ chain and of human fibrinogen αE and β chains in the region surrounding the human W253 residue. Human (P02679-2), mouse (Q8VCM7; from TrEMBL), rat (P02680-2), cow (P12799), chicken (NP_990320; from NCBI), Xenopus (P17634), and lamprey (P04115) fibrinogen γ sequences, as well as human fibrinogen αE (P02671) and β sequences (P02675) were obtained from the Swiss-Prot database, if not otherwise indicated, and aligned using the ClustalW program (http://www.ebi.ac.uk/clustalw/). Residue numbering is from the first ATG codon. Identical amino acids are shaded black. The human W253 residue is indicated by the arrow.

Figure 3. Crystallographic structure analysis of the γ D domain. (A) View of the γ C-terminal fragment with the position of W253 (W227 in the mature protein) in the central antiparallel β sheet, with helix highlighted in green, and β strands in orange. (B) W253 (W227) forms two H-bonds (green) with F241 (F215 in the mature protein), while (C) the W253C mutation may create a third H-bond. (D) W253 (W227) is buried and surrounded by polar (yellow) and non-polar (grey) amino acids, within a 4 Å radius. (E) Replacement with a cysteine residue creates a void, possibly leading to local refolding. Figures were prepared using Swiss-PdbViewer and POV-Ray from the PDB file 1FIB.
RESULTS AND DISCUSSION

The patient presented as a classical case of hypofibrinogenemia with a proportional decrease in fibrinogen coagulant and antigen levels (0.7 g/l and 0.8 g/l, respectively). She also had a prolonged thrombin time (31 s, normal range 16–21 s). The aPTT was also slightly prolonged (ratio 1.25, normal range 0.8 to 1.2), while PT, other coagulation factor levels, and vWF Ag were within the normal range.

Despite moderate fibrinogen deficiency the patient experienced several bleeding episodes as well as a spontaneous abortion, which was not explained by examination of the placenta or by genetic analysis of the fetus. The bleeding episodes were either spontaneous (epistaxis in childhood) or provoked (both extractions and postpartum). The initial course of the first spontaneous delivery was normal; the development of a large pararectal haematoma was provoked by the episiotomy probably potentiated by hypofibrinogenemia, with rapid lysis of the weak fibrin clot. Haemotherapy with three units of RBC, plasma, and 3.0 g fibrinogen prevented the bleeding complications of surgical revision of the haematoma. However, mild bleeding occurred again following the second spontaneous delivery without episiotomy, despite preventive administration of 3.0 g fibrinogen which resulted in a circulating fibrinogen level of 1.6 g/l. In contrast, preoperative infusion of the same dose of fibrinogen was sufficient to prevent the bleeding complication after laparoscopic surgery carried out six years later. This supports the suggestion that injury or surgical interventions on parenchymous organs with physiologically high fibrinolytic potential may require more intensive fibrinogen replacement therapy in patients with hypofibrinogenemia and a history of a bleeding tendency.

Sequence analysis of genomic DNA revealed no mutation in either FGA or FGB; in contrast, a novel missense mutation—TGG→TGT, W253C (fibrinogen Bratislava)—was identified in FGG exon 7. The localisation of this missense mutation close to the previously reported mutations Matsumoto IV16 and Hakata17 prompted us to undertake co-transfection experiments in COS-7 cells in order to assay its effects on fibrinogen assembly and secretion and confirm its causative nature.

The FGG W253C mutant cDNA, obtained by site directed mutagenesis of the wild-type FGG cDNA as described in Methods, was transiently co-transfected in COS-7 cells with wild-type FGA and FGB cDNAs. Three negative controls for intracellular hexamer assembly were also produced and analysed in the same way. These were FGG 1413X, K411X, and K406X, corresponding to a deletion of 25, 27, and 32 residues, respectively, from the γ chain C-terminus.12 Forty eight hours after transfection, individual fibrinogen chains (under reducing conditions) or assembled hexamers (under non-reducing conditions) in cell extracts and conditioned media were detected by western blot analysis with a polyclonal antifibrinogen antibody.

Co-transfection with the three cDNAs showed expression of all three polypeptides, normal assembly inside the cell, and adequate secretion of the hexamer (fig 1). When co-transfections were undertaken with wild-type FGA and FGB cDNAs in combination with the mutant FGG W253C cDNA, the three polypeptides were expressed and were able to assemble intracellularly to form apparently normal hexamers. In contrast, co-expression of wild-type FGA and FGB with mutant FGG W253C cDNA abolished the secretion into the media of the mutant γ chain, as well as the mutant containing hexamer.

Surprisingly, under these conditions—when co-transfections were carried out with wild type FGA and FGB cDNAs and with the mutant I413X FGG, which we had designed as a negative control for hexamer assembly—a band corresponding to the hexamer was detectable in cell lysates, although this was always fainter than the wild type band. This result appears to contradict data from a recent study12 showing that no hexamer is detected when this truncated γ chain is cotransfected in CHO cells. In order to assess whether such differences could be attributable to a greater permissiveness of COS cells to incorporate truncated γ chains into hexamers, we analysed two more severely truncated variants: K411X and K406X. In both cases, the hexamer was absent or barely detectable. These data confirm the validity of our in vitro transfected COS-7 cell system for distinguishing between defects in fibrinogen assembly and secretion, even though it is not identical to the CHO model.

Residue W253 (W227 in the mature protein) is absolutely conserved in seven species from lamprey to human, as well as in the human fibrinogen αE and β chains (fig 2). In the γ chain, it is surrounded by many hydrophobic residues and buried in a central β strand (fig 3A). The crystallographic structure of the γ chain suggests that the backbone of W253 (W227) forms two H-bonds with the backbone of F241 (F215 in the mature protein, fig 3B). Substitution of W to C is predicted to add another H-bond between both residues (fig 3C). Furthermore the replacement of W by the smaller C may create a void leading to local refolding in order to close the gap (fig 3D, 3E), possibly destabilising the normal folding of the γC domain and causing the non-secretion of fibrinogen hexamers. Interestingly, in the fibrinogen molecule there appears to be no potential partner for disulphide bridge formation with the new cysteine residue within a radius of 10 Å. Nevertheless, it is conceivable that the novel free –SH group interacts with reactive sulphhydril groups of other proteins present in the cell—for example, albumin, particularly in the endoplasmic reticulum.

The study of this novel mutation provides new insight into the process of fibrinogen assembly and secretion. Indeed, mutations specifically inhibiting fibrinogen secretion (and not assembly) have previously been identified in the C-terminal portion of the β chain,29 30 31 suggesting a preferential role of this domain as a target for quality control of hexamer secretion. In contrast, in a study of serial deletions of the γ chain, truncation of the last 25 C-terminal residues or more was shown to prevent the assembly of the hexamer in CHO cells.32 Similarly the γC179R Matsumoto IV variant fails to form α2/γ and βB/γ complexes, which are the normal assembly intermediates of fibrinogen.33 Interpreted as these observations might lead to the simple conclusion that the β C-terminal domain is critical for fibrinogen secretion, whereas the γ C-terminal domain is essential for fibrinogen assembly. Our current analysis of fibrinogen Bratislava, together with other γ mutants such as fibrinogen Brescia34 G310R and Aguadilla35 R401W—which also abolish secretion and also cause an intriguing hepatic endoplasmic reticulum storage disease—indicates that the domains important for the processes of hexamer assembly and hexamer secretion should not be considered as being restricted to one or other fibrinogen chain.

ACKNOWLEDGEMENTS

We thank Holger Scheib for helpful comments on the crystallographic analysis. This study was supported by Swiss National Science Foundation (SNF) grant No 31-64987.01, by the Téléthon Action Suisse Foundation, the Ernst and Lucie Schmidheiny Foundation and a Bayer Hemophilia Special Project award. MNA is the recipient of an SNF professorship (No 631-66023).

Authors' affiliations
D Vu, L Palumbo, M Neerman-Arbez, Department of Genetic Medicine and Development, University Medical School, Geneva, Switzerland
P de Moerloose, Division of Angiology and Haemostasis, University Hospital, Geneva
REFERENCES


